<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00210</drugbank-id>
  <drugbank-id>APRD00780</drugbank-id>
  <name>Adapalene</name>
  <description>Adapalene is a member of the retinoid drug class that is typically found in topical formulations used for the treatment of acne. It may be used to treat keratosis pilaris as well as other skin conditions as off-label use. It is marketed by Galderma under the trade names Differin and Adaferin.</description>
  <cas-number>106685-40-9</cas-number>
  <unii>1L4806J2QF</unii>
  <average-mass>412.5201</average-mass>
  <monoisotopic-mass>412.203844762</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A314</ref-id>
        <pubmed-id>14619325</pubmed-id>
        <citation>Rolewski SL: Clinical review: topical retinoids. Dermatol Nurs. 2003 Oct;15(5):447-50, 459-65.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Graziano Castaldi, Pietro Allegrini, Gabriele Razzetti, Mauro Ercoli, "Process for the preparation of adapalene." U.S. Patent US20060229465, issued October 12, 2006.</synthesis-reference>
  <indication>For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.</indication>
  <pharmacodynamics>Adapalene is a chemically stable retinoid-like compound. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris.</pharmacodynamics>
  <mechanism-of-action>Mechanistically, adapalene binds to specific retinoic acid nuclear receptors (gamma and beta) and retinoid X receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene may normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.</mechanism-of-action>
  <toxicity>The acute oral toxicity of adapalene in mice and rats is greater than 10 mL/kg. Chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.</toxicity>
  <metabolism>Metabolized mainly by O-demethylation, hydroxylation and conjugation, and excretion is primarily by the biliary route.</metabolism>
  <absorption>Adapalene displays a limited absorption potential across the human skin. Only trace amounts (&lt;0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Excretion appears to be primarily by the biliary route.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.</description>
    <direct-parent>Retinoids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Prenol lipids</class>
    <subclass>Retinoids</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Anisoles</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Methoxybenzenes</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Naphthalenecarboxylic acids</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Phenylnaphthalenes</alternative-parent>
    <substituent>2-naphthalenecarboxylic acid</substituent>
    <substituent>2-naphthalenecarboxylic acid or derivatives</substituent>
    <substituent>Adapalene</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methoxybenzene</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Naphthalene</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Phenylnaphthalene</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid</synonym>
    <synonym language="english" coder="inn/usan">Adapalene</synonym>
    <synonym language="french" coder="inn">Adapalène</synonym>
    <synonym language="spanish" coder="inn">Adapaleno</synonym>
    <synonym language="latin" coder="inn">Adapalenum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Adapalene</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6132</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090962</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Physicians Total Caer, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090824</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-4155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020380</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Owen Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>69007-912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength>.1 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA022502</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Owen Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>69007-918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA021753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1377</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208322</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1267</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-02</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090962</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Perrigo New York Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>45802-453</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.1 g/100g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020748</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Pru Gen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42546-720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>45 g/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0472-0126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA201000</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA021753</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0168-0424</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090824</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA203981</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>69842-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Safeway, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>21130-708</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Sandoz Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA200298</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Call Inc. (Dba Rochester Pharmaceuticals)</labeller>
      <ndc-id/>
      <ndc-product-code>49908-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Swab</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA204593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>L’Oreal USA Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code>49967-354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091314</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-6301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090962</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene 0.1% / Benzoyl Peroxide 2.5% / Clindamycin 1%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene 0.1% / Benzoyl Peroxide 2.5% / Niacinamide 4%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene 0.3% / Benzoyl Peroxide 2.5% / Clindamycin 1%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene 0.3% / Benzoyl Peroxide 2.5% / Niacinamide 4%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene 0.3% / Niacinamide 4%</name>
      <labeller>Sincerus Florida, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>72934-1006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene and Benzoyl Peroxide</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-869</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA022320</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ADAPALENE and BENZOYL PEROXIDE</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1364</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA206959</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene and Benzoyl Peroxide</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0472-0310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA203790</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene and Benzoyl Peroxide</name>
      <labeller>Perrigo New York Inc</labeller>
      <ndc-id/>
      <ndc-product-code>45802-846</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA205033</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene and Benzoyl Peroxide</name>
      <labeller>Sandoz Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7182</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA206164</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene and Benzoyl Peroxide</name>
      <labeller>Glenmark Pharmaceuticals Inc., USA</labeller>
      <ndc-id/>
      <ndc-product-code>68462-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA208108</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene Topical Solution</name>
      <labeller>Call Inc. (Dba Rochester Pharmaceuticals)</labeller>
      <ndc-id/>
      <ndc-product-code>49908-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA203981</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene Topical Solution</name>
      <labeller>Marnel Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0682-0053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Swab</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA204593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adapalene Topical Solution</name>
      <labeller>Allegis Holdings LLC</labeller>
      <ndc-id/>
      <ndc-product-code>71297-410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA203981</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clindap-T</name>
      <labeller>Accumix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69167-1015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2015-07-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>DPT Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>63094-5905</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-28</started-marketing-on>
      <ended-marketing-on>2006-01-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA020338</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5271</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020748</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA022502</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5958</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA021753</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020380</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020380</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>3 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA021753</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength>0.1 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA022502</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020748</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma Laboratories, L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>0299-4910</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020380</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148749</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>0.1 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231592</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.1 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148757</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-08</started-marketing-on>
      <ended-marketing-on>2003-07-08</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>0.1 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Differin</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02376660</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength>0.1 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Differin Xp</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274000</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Epiduo</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5991</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA022320</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epiduo</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5908</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA022320</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epiduo Forte</name>
      <labeller>Galderma Laboratories, L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>0299-5906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>NDA207917</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuvya</name>
      <labeller>Accumix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69167-0485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2015-07-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Proactiv MD Adapalene Acne Treatment</name>
      <labeller>The Proactiv Company, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>11410-956</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>0.1 g/100g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020380</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoz Adapalene/benzoyl Peroxide</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02489007</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tactupump</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365871</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tactupump Forte</name>
      <labeller>Galderma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02446235</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Taro-adapalene/benzoyl Peroxide</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456923</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Adaferin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Differine</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Epiduo</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Clindap-T</name>
      <ingredients>Adapalene + Clindamycin</ingredients>
    </mixture>
    <mixture>
      <name>Nuvya</name>
      <ingredients>Adapalene + Diclofenac + Tamoxifen</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene Topical Solution</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Proactiv MD Adapalene Acne Treatment</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene and Benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>ADAPALENE and BENZOYL PEROXIDE</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Epiduo</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene and Benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene and Benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene Topical Solution</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene 0.3% / Benzoyl Peroxide 2.5% / Clindamycin 1%</name>
      <ingredients>Adapalene + Benzoyl peroxide + Clindamycin</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene 0.3% / Benzoyl Peroxide 2.5% / Niacinamide 4%</name>
      <ingredients>Adapalene + Benzoyl peroxide + Nicotinamide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene 0.3% / Niacinamide 4%</name>
      <ingredients>Adapalene + Nicotinamide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene 0.1% / Benzoyl Peroxide 2.5% / Clindamycin 1%</name>
      <ingredients>Adapalene + Benzoyl peroxide + Clindamycin</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene 0.1% / Benzoyl Peroxide 2.5% / Niacinamide 4%</name>
      <ingredients>Adapalene + Benzoyl peroxide + Nicotinamide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene and Benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene Topical Solution</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene and Benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Adapalene</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Epiduo Forte</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin Xp</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Tactupump</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Differin</name>
      <ingredients>Adapalene</ingredients>
    </mixture>
    <mixture>
      <name>Tactupump Forte</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Adapalene/benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
    <mixture>
      <name>Taro-adapalene/benzoyl Peroxide</name>
      <ingredients>Adapalene + Benzoyl peroxide</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Ameri-Pac Inc.</name>
      <url>http://www.ameri-pac.com</url>
    </packager>
    <packager>
      <name>DPT Laboratories Ltd.</name>
      <url>http://www.dptlabs.com</url>
    </packager>
    <packager>
      <name>E. Fougera and Co.</name>
      <url>http://www.fougera.com</url>
    </packager>
    <packager>
      <name>Galderma Laboratories</name>
      <url>http://www.galderma.com</url>
    </packager>
    <packager>
      <name>Glenmark Generics Ltd.</name>
      <url>http://www.glenmark-generics.com</url>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">Nycomed us inc</manufacturer>
    <manufacturer generic="false" url="">Galderma laboratories lp</manufacturer>
    <manufacturer generic="true" url="">Glenmark generics inc usa</manufacturer>
    <manufacturer generic="true" url="">Pliva hrvatska doo</manufacturer>
    <manufacturer generic="false" url="">Galderma research and development inc</manufacturer>
    <manufacturer generic="false" url="">Galderma Laboratories</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Differin 0.1% cream</description>
      <cost currency="USD">4.85</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Differin 0.3% Gel 45 gm Tube</description>
      <cost currency="USD">219.65</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Differin 0.1% Cream 45 gm Tube</description>
      <cost currency="USD">227.13</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Differin 0.1% Gel 45 gm Tube</description>
      <cost currency="USD">227.13</cost>
      <unit>tube</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Analgesics</category>
      <mesh-id>D000700</mesh-id>
    </category>
    <category>
      <category>Analgesics, Non-Narcotic</category>
      <mesh-id>D018712</mesh-id>
    </category>
    <category>
      <category>Anti-Acne Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Acne Preparations for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Misc. Skin and Mucous Membrane Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Naphthalenes</category>
      <mesh-id>D009281</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Retinoids</category>
      <mesh-id>D012176</mesh-id>
    </category>
    <category>
      <category>Retinoids for Topical Use in Acne</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.1 g/100g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>1 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>1 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>45 g/1g</strength>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength>.1 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Swab</form>
      <route>Topical</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>3 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength>0.1 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength>1 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>0.1 g/100g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D10AD03">
      <level code="D10AD">Retinoids for topical use in acne</level>
      <level code="D10A">ANTI-ACNE PREPARATIONS FOR TOPICAL USE</level>
      <level code="D10">ANTI-ACNE PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="D10AD53">
      <level code="D10AD">Retinoids for topical use in acne</level>
      <level code="D10A">ANTI-ACNE PREPARATIONS FOR TOPICAL USE</level>
      <level code="D10">ANTI-ACNE PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>84:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00210.pdf?1265922800</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00210.pdf?1265922740</msds>
  <patents>
    <patent>
      <number>4717720</number>
      <country>United States</country>
      <approved>1988-01-05</approved>
      <expires>2010-05-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8909305</number>
      <country>United States</country>
      <approved>2014-12-09</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7579377</number>
      <country>United States</country>
      <approved>2009-08-25</approved>
      <expires>2025-02-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7834060</number>
      <country>United States</country>
      <approved>2010-11-16</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7868044</number>
      <country>United States</country>
      <approved>2011-01-11</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8703820</number>
      <country>United States</country>
      <approved>2014-04-22</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7838558</number>
      <country>United States</country>
      <approved>2010-11-23</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7737181</number>
      <country>United States</country>
      <approved>2010-06-15</approved>
      <expires>2024-08-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7964202</number>
      <country>United States</country>
      <approved>2011-06-21</approved>
      <expires>2024-09-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8071644</number>
      <country>United States</country>
      <approved>2011-12-06</approved>
      <expires>2027-07-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8080537</number>
      <country>United States</country>
      <approved>2011-12-20</approved>
      <expires>2027-07-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8105618</number>
      <country>United States</country>
      <approved>2012-01-31</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8129362</number>
      <country>United States</country>
      <approved>2012-03-06</approved>
      <expires>2027-07-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8445543</number>
      <country>United States</country>
      <approved>2013-05-21</approved>
      <expires>2027-07-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8809305</number>
      <country>United States</country>
      <approved>2014-08-19</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8936800</number>
      <country>United States</country>
      <approved>2015-01-20</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8241649</number>
      <country>United States</country>
      <approved>2012-08-14</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7820186</number>
      <country>United States</country>
      <approved>2010-10-26</approved>
      <expires>2025-11-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7998467</number>
      <country>United States</country>
      <approved>2011-08-16</approved>
      <expires>2028-05-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8435502</number>
      <country>United States</country>
      <approved>2013-05-07</approved>
      <expires>2026-09-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8709392</number>
      <country>United States</country>
      <approved>2014-04-29</approved>
      <expires>2026-09-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8785420</number>
      <country>United States</country>
      <approved>2014-07-22</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8729127</number>
      <country>United States</country>
      <approved>2014-05-20</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9381179</number>
      <country>United States</country>
      <approved>2016-07-05</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9387187</number>
      <country>United States</country>
      <approved>2016-07-12</approved>
      <expires>2023-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9814690</number>
      <country>United States</country>
      <approved>2017-11-14</approved>
      <expires>2022-12-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Adapalene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>The risk or severity of adverse effects can be increased when Resorcinol is combined with Adapalene.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>6.06</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.01e-06 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>6.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>differin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>412.5201</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>412.203844762</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C28H28O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LZCDAPDGXCYOEH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>46.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>122.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>47.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Practically Insoluble</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>8.6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>224</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31174</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>60164</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505019</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01112</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>54244</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50048280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448047</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000115</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Adapalene</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1265</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/adapalene.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dif1134.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/adapalene-cream.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000144</id>
      <name>Retinoic acid receptor gamma</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P13631" source="Swiss-Prot">
        <name>Retinoic acid receptor gamma</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).</specific-function>
        <gene-name>RARG</gene-name>
        <locus>12q13</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.52</theoretical-pi>
        <molecular-weight>50341.405</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9866</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RARG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M24857</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>306887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P13631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RARG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR1B3</synonym>
          <synonym>Nuclear receptor subfamily 1 group B member 3</synonym>
          <synonym>RAR-gamma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000287|Retinoic acid receptor gamma
MATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMAS
LSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK
NMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSPDSY
ELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIK
IVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMH
NAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLEA
LRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPE
MFEDDSSQPGPHPNASSEDEVPGGQGKGGLKSPA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020450|Retinoic acid receptor gamma (RARG)
ATGGCCACCAATAAGGAGCGACTCTTTGCGGCTGGTGCCCTGGGGCCTGGATCTGGCTAC
CCAGGGGCAGGTTTCCCCTTCGCCTTCCCAGGGGCACTCAGGGGGTCTCCGCCTTTCGAG
ATGCTGAGCCCTAGCTTCCGGGGCCTGGGCCAGCCTGACCTCCCCAAGGAGATGGCCTCT
CTGTCGGTGGAGACACAGAGCACCAGCTCAGAGGAGATGGTGCCCAGCTCGCCCTCGCCC
CCTCCGCCTCCTCGGGTCTACAAGCCATGCTTCGTGTGCAATGACAAGTCCTCTGGCTAC
CACTATGGGGTCAGCTCTTGTGAAGGCTGCAAGGGCTTCTTTCGCCGAAGCATCCAGAAG
AACATGGTGTACACGTGTCACCGCGACAAAAACTGTATCATCAACAAGGTGACCAGGAAT
CGCTGCCAGTACTGCCGGCTACAGAAGTGCTTCGAAGTGGGCATGTCCAAGGAAGCTGTG
CGAAATGACCGGAACAAGAAGAAGAAAGAGGTGAAGGAAGAAGGGTCACCTGACAGCTAT
GAGCTGAGCCCTCAGTTAGAAGAGCTCATCACCAAGGTCAGCAAAGCCCATCAGGAGACT
TTCCCCTCGCTCTGCCAGCTGGGCAAGTATACCACGAACTCCAGTGCAGACCACCGCGTG
CAGCTGGATCTGGGGCTGTGGGACAAGTTCAGTGAGCTGGCTACCAAGTGCATCATCAAG
ATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCTCAGCATTGCTGACCAGATC
ACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATGCTGCGTATCTGCACAAGGTACACC
CCAGAGCAGGACACCATGACCTTCTCCGACGGGCTGACCCTGAACCGGACCCAGATGCAC
AATGCCGGCTTCGGGCCCCTCACAGACCTTGTCTTTGCCTTTGCTGGGCAGCTCCTGCCC
CTGGAGATGGATGACACCGAGACAGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGAC
CGCATGGACCTGGAGGAGCCCGAAAAAGTGGACAAGCTGCAGGAGCCACTGCTGGAAGCC
CTGAGGCTGTACGCCCGGCGCCGGCGGCCCAGCCAGCCCTACATGTTCCCAAGGATGCTA
ATGAAAATCACCGACCTCCGGGGCATCAGCACTAAGGGAGCTGAAAGGGCCATTACTCTG
AAGATGGAGATTCCAGGCCCGATGCCTCCCTTAATCCGAGAGATGCTGGAGAACCCTGAA
ATGTTTGAGGATGACTCCTCGCAGCCTGGTCCCCACCCCAATGCCTCTAGCGAGGATGAG
GTTCCTGGGGGCCAGGGCAAAGGGGGCCTGAAGTCCCCAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoid X receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anterior/posterior pattern specification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>canonical Wnt signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic eye morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic hindlimb morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>face development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glandular epithelial cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>growth plate cartilage chondrocyte growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Harderian gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of chondrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neural tube closure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate gland epithelium morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell size</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of myelination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of myeloid cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal pigment epithelium development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>trachea cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000206</id>
      <name>Retinoic acid receptor beta</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4312</ref-id>
            <pubmed-id>9204085</pubmed-id>
            <citation>Shroot B, Michel S: Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103.</citation>
          </article>
          <article>
            <ref-id>A4315</ref-id>
            <pubmed-id>9557255</pubmed-id>
            <citation>Shroot B, Michel S, Allec J, Chatelus A, Wagner N: A new concept of drug delivery for acne. Dermatology. 1998;196(1):165-70.</citation>
          </article>
          <article>
            <ref-id>A4314</ref-id>
            <pubmed-id>9990413</pubmed-id>
            <citation>Michel S, Jomard A, Demarchez M: Pharmacology of adapalene. Br J Dermatol. 1998 Oct;139 Suppl 52:3-7.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P10826" source="Swiss-Prot">
        <name>Retinoic acid receptor beta</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function.</specific-function>
        <gene-name>RARB</gene-name>
        <locus>3p24</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.86</theoretical-pi>
        <molecular-weight>50488.63</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9865</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RARB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X07282</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35883</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>591</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>591</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10826</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RARB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>HAP</synonym>
          <synonym>HBV-activated protein</synonym>
          <synonym>NR1B2</synonym>
          <synonym>Nuclear receptor subfamily 1 group B member 2</synonym>
          <synonym>RAR-beta</synonym>
          <synonym>RAR-epsilon</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000411|Retinoic acid receptor beta
MTTSGHACPVPAVNGHMTHYPATPYPLLFPPVIGGLSLPPLHGLHGHPPPSGCSTPSPAT
IETQSTSSEELVPSPPSPLPPPRVYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNM
IYTCHRDKNCVINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKETSKQECTESYEM
TAELDDLTEKIRKAHQETFPSLCQLGKYTTNSSADHRVRLDLGLWDKFSELATKCIIKIV
EFAKRLPGFTGLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNA
GFGPLTDLVFTFANQLLPLEMDDTETGLLSAICLICGDRQDLEEPTKVDKLQEPLLEALK
IYIRKRRPSKPHMFPKILMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGH
EPLTPSSSGNTAEHSPSISPSSVENSGVSQSPLVQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010005|Retinoic acid receptor beta (RARB)
ATGTTTGACTGTATGGATGTTCTGTCAGTGAGTCCTGGGCAAATCCTGGATTTCTACACT
GCGAGTCCGTCTTCCTGCATGCTCCAGGAGAAAGCTCTCAAAGCATGCTTCAGTGGATTG
ACCCAAACCGAATGGCAGCATCGGCACACTGCTCAATCAATTGAAACACAGAGCACCAGC
TCTGAGGAACTCGTCCCAAGCCCCCCATCTCCACTTCCTCCCCCTCGAGTGTACAAACCC
TGCTTCGTCTGCCAGGACAAATCATCAGGGTACCACTATGGGGTCAGCGCCTGTGAGGGA
TGTAAGGGCTTTTTCCGCAGAAGTATTCAGAAGAATATGATTTACACTTGTCACCGAGAT
AAGAACTGTGTTATTAATAAAGTCACCAGGAATCGATGCCAATACTGTCGACTCCAGAAG
TGCTTTGAAGTGGGAATGTCCAAAGAATCTGTCAGGAATGACAGGAACAAGAAAAAGAAG
GAGACTTCGAAGCAAGAATGCACAGAGAGCTATGAAATGACAGCTGAGTTGGACGATCTC
ACAGAGAAGATCCGAAAAGCTCACCAGGAAACTTTCCCTTCACTCTGCCAGCTGGGTAAA
TACACCACGAATTCCAGTGCTGACCATCGAGTCCGACTGGACCTGGGCCTCTGGGACAAA
TTCAGTGAACTGGCCACCAAGTGCATTATTAAGATCGTGGAGTTTGCTAAACGTCTGCCT
GGTTTCACTGGCTTGACCATCGCAGACCAAATTACCCTGCTGAAGGCCGCCTGCCTGGAC
ATCCTGATTCTTAGAATTTGCACCAGGTATACCCCAGAACAAGACACCATGACTTTCTCA
GACGGCCTTACCCTAAATCGAACTCAGATGCACAATGCTGGATTTGGTCCTCTGACTGAC
CTTGTGTTCACCTTTGCCAACCAGCTCCTGCCTTTGGAAATGGATGACACAGAAACAGGC
CTTCTCAGTGCCATCTGCTTAATCTGTGGAGACCGCCAGGACCTTGAGGAACCGACAAAA
GTAGATAAGCTACAAGAACCATTGCTGGAAGCACTAAAAATTTATATCAGAAAAAGACGA
CCCAGCAAGCCTCACATGTTTCCAAAGATCTTAATGAAAATCACAGATCTCCGTAGCATC
AGTGCTAAAGGTGCAGAGCGTGTAATTACCTTGAAAATGGAAATTCCTGGATCAATGCCA
CCTCTCATTCAAGAAATGCTGGAGAATTCTGAAGGACATGAACCCTTGACCCCAAGTTCA
AGTGGGAACACAGCAGAGCACAGTCCTAGCATCTCACCCAGCTCAGTGGAAAACAGTGGG
GTCAGTCAGTCACCACTCGTGCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of myelination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000707</id>
      <name>Retinoic acid receptor RXR-gamma</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A4316</ref-id>
            <pubmed-id>10651997</pubmed-id>
            <citation>Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48443" source="Swiss-Prot">
        <name>Retinoic acid receptor RXR-gamma</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid (By similarity).</specific-function>
        <gene-name>RXRG</gene-name>
        <locus>1q22-q23</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.67</theoretical-pi>
        <molecular-weight>50870.72</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10479</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RXRG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U38480</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1053069</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>612</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>612</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P48443</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RXRG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR2B3</synonym>
          <synonym>Nuclear receptor subfamily 2 group B member 3</synonym>
          <synonym>Retinoid X receptor gamma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016185|Retinoic acid receptor RXR-gamma
MYGNYSHFMKFPAGYGGSPGHTGSTSMSPSAALSTGKPMDSHPSYTDTPVSAPRTLSAVG
TPLNALGSPYRVITSAMGPPSGALAAPPGINLVAPPSSQLNVVNSVSSSEDIKPLPGLPG
IGNMNYPSTSPGSLVKHICAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLIYTCRDNKD
CLIDKRQRNRCQYCRYQKCLVMGMKREAVQEERQRSRERAESEAECATSGHEDMPVERIL
EAELAVEPKTESYGDMNMENSTNDPVTNICHAADKQLFTLVEWAKRIPHFSDLTLEDQVI
LLRAGWNELLIASFSHRSVSVQDGILLATGLHVHRSSAHSAGVGSIFDRVLTELVSKMKD
MQMDKSELGCLRAIVLFNPDAKGLSNPSEVETLREKVYATLEAYTKQKYPEQPGRFAKLL
LRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLETPLQIT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0001409|1392 bp
ATGTATGGAAATTATTCTCACTTCATGAAGTTTCCCGCAGGCTATGGAGGCTCCCCTGGC
CACACTGGCTCTACATCCATGAGCCCATCAGCAGCCTTGTCCACAGGGAAGCCAATGGAC
AGCCACCCCAGCTACACAGATACCCCAGTGAGTGCCCCACGGACTCTGAGTGCAGTGGGG
ACCCCCCTCAATGCCCTGGGCTCTCCATATCGAGTCATCACCTCTGCCATGGGCCCACCC
TCAGGAGCACTTGCAGCGCCTCCAGGAATCAACTTGGTTGCCCCACCCAGCTCTCAGCTA
AATGTGGTCAACAGTGTCAGCAGTTCAGAGGACATCAAGCCCTTACCAGGGCTTCCCGGG
ATTGGAAACATGAACTACCCATCCACCAGCCCCGGATCTCTGGTTAAACACATCTGTGCT
ATCTGTGGAGACAGATCCTCAGGAAAGCACTACGGGGTATACAGTTGTGAAGGCTGCAAA
GGGTTCTTCAAGAGGACGATAAGGAAGGACCTCATCTACACGTGTCGGGATAATAAAGAC
TGCCTCATTGACAAGCGTCAGCGCAACCGCTGCCAGTACTGTCGCTATCAGAAGTGCCTT
GTCATGGGCATGAAGAGGGAAGCTGTGCAAGAAGAAAGACAGAGGAGCCGAGAGCGAGCT
GAGAGTGAGGCAGAATGTGCTACCAGTGGTCATGAAGACATGCCTGTGGAGAGGATTCTA
GAAGCTGAACTTGCTGTTGAACCAAAGACAGAATCCTATGGTGACATGAATATGGAGAAC
TCGACAAATGACCCTGTTACCAACATATGTCATGCTGCTGACAAGCAGCTTTTCACCCTC
GTTGAATGGGCCAAGCGTATTCCCCACTTCTCTGACCTCACCTTGGAGGACCAGGTCATT
TTGCTTCGGGCAGGGTGGAATGAATTGCTGATTGCCTCTTTCTCCCACCGCTCAGTTTCC
GTGCAGGATGGCATCCTTCTGGCCACGGGTTTACATGTCCACCGGAGCAGTGCCCACAGT
GCTGGGGTCGGCTCCATCTTTGACAGAGTTCTAACTGAGCTGGTTTCCAAAATGAAAGAC
ATGCAGATGGACAAGTCGGAACTGGGATGCCTGCGAGCCATTGTACTCTTTAACCCAGAT
GCCAAGGGCCTGTCCAACCCCTCTGAGGTGGAGACTCTGCGAGAGAAGGTTTATGCCACC
CTTGAGGCCTACACCAAGCAGAAGTATCCGGAACAGCCAGGCAGGTTTGCCAAGCTGCTG
CTGCGCCTCCCAGCTCTGCGTTCCATTGGCTTGAAATGCCTGGAGCACCTCTTCTTCTTC
AAGCTCATCGGGGACACCCCCATTGACACCTTCCTCATGGAGATGTTGGAGACCCCGCTG
CAGATCACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF11825</identifier>
            <name>Nuc_recep-AF1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>9-cis retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000078</id>
      <name>Retinoic acid receptor RXR-beta</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A4316</ref-id>
            <pubmed-id>10651997</pubmed-id>
            <citation>Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P28702" source="Swiss-Prot">
        <name>Retinoic acid receptor RXR-beta</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (By similarity). Specifically binds 9-cis retinoic acid (9C-RA).</specific-function>
        <gene-name>RXRB</gene-name>
        <locus>6p21.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.24</theoretical-pi>
        <molecular-weight>56921.38</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10478</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RXRB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X63522</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>30448</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>611</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>611</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28702</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RXRB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR2B2</synonym>
          <synonym>Nuclear receptor subfamily 2 group B member 2</synonym>
          <synonym>Retinoid X receptor beta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000156|Retinoic acid receptor RXR-beta
MSWAARPPFLPQRHAAGQCGPVGVRKEMHCGVASRWRRRRPWLDPAAAAAAAVAGGEQQT
PEPEPGEAGRDGMGDSGRDSRSPDSSSPNPLPQGVPPPSPPGPPLPPSTAPSLGGSGAPP
PPPMPPPPLGSPFPVISSSMGSPGLPPPAPPGFSGPVSSPQINSTVSLPGGGSGPPEDVK
PPVLGVRGLHCPPPPGGPGAGKRLCAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLTYS
CRDNKDCTVDKRQRNRCQYCRYQKCLATGMKREAVQEERQRGKDKDGDGEGAGGAPEEMP
VDRILEAELAVEQKSDQGVEGPGGTGGSGSSPNDPVTNICQAADKQLFTLVEWAKRIPHF
SSLPLDDQVILLRAGWNELLIASFSHRSIDVRDGILLATGLHVHRNSAHSAGVGAIFDRV
LTELVSKMRDMRMDKTELGCLRAIILFNPDAKGLSNPSEVEVLREKVYASLETYCKQKYP
EQQGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQLA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016010|Retinoic acid receptor RXR-beta (RXRB)
ATGTCTTGGGCCGCTCGCCCGCCCTTCCTCCCTCAGCGGCATGCCGCAGGGCAGTGTGGG
CCGGTGGGGGTGCGAAAAGAAATGCATTGTGGGGTCGCGTCCCGGTGGCGGCGGCGACGG
CCCTGGCTGGATCCCGCAGCGGCGGCGGCGGCGGCGGTGGCAGGCGGAGAACAACAAACC
CCGGAGCCGGAGCCAGGGGAGGCTGGACGGGACGGGATGGGCGACAGCGGGCGGGACTCC
CGAAGCCCAGACAGCTCCTCCCCAAATCCCCTTCCCCAGGGAGTCCCTCCCCCTTCTCCT
CCTGGGCCACCCCTACCCCCTTCAACAGCTCCATCCCTTGGAGGCTCTGGGGCCCCACCC
CCACCCCCGATGCCACCACCCCCACTGGGCTCTCCCTTTCCAGTCATCAGTTCTTCCATG
GGGTCCCCTGGTCTGCCCCCTCCAGCTCCCCCAGGATTCTCCGGGCCTGTCAGCAGCCCC
CAGATTAACTCAACAGTGTCACTCCCTGGGGGTGGGTCTGGCCCCCCTGAAGATGTGAAG
CCACCAGTCTTAGGGGTCCGGGGCCTGCACTGTCCACCCCCTCCAGGTGGCCCTGGGGCT
GGCAAACGGCTATGTGCAATCTGCGGGGACAGAAGCTCAGGCAAACACTACGGGGTTTAC
AGCTGTGAGGGTTGCAAGGGCTTCTTCAAACGCACCATCCGCAAAGACCTTACATACTCT
TGCCGGGACAACAAAGACTGCACAGTGGACAAGCGCCAGCGGAACCGCTGTCAGTACTGC
CGCTATCAGAAGTGCCTGGCCACTGGCATGAAGAGGGAGGCGGTACAGGAGGAGCGTCAG
CGGGGAAAGGACAAGGATGGGGATGGGGAGGGGGCTGGGGGAGCCCCCGAGGAGATGCCT
GTGGACAGGATCCTGGAGGCAGAGCTTGCTGTGGAACAGAAGAGTGACCAGGGCGTTGAG
GGTCCTGGGGGAACCGGGGGTAGCGGCAGCAGCCCAAATGACCCTGTGACTAACATCTGT
CAGGCAGCTGACAAACAGCTATTCACGCTTGTTGAGTGGGCGAAGAGGATCCCACACTTT
TCCTCCTTGCCTCTGGATGATCAGGTCATATTGCTGCGGGCAGGCTGGAATGAACTCCTC
ATTGCCTCCTTCTCACACCGATCCATTGATGTTCGAGATGGCATCCTCCTTGCCACAGGT
CTTCACGTGCACCGCAACTCAGCCCATTCAGCAGGAGTAGGAGCCATCTTTGATCGGTCC
CTCTCCAGGGTGCTGACAGAGCTAGTGTCCAAAATGCGTGACATGAGGATGGACAAGACA
GAGCTTGGCTGCCTGAGGGCAATCATTCTGTTTAATCCAGATGCCAAGGGCCTCTCCAAC
CCTAGTGAGGTGGAGGTCCTGCGGGAGAAAGTGTATGCATCACTGGAGACCTACTGCAAA
CAGAAGTACCCTGAGCAGCAGGGACGGTTTGCCAAGCTGCTGCTACGTCTTCCTGCCCTC
CGGTCCATTGGCCTTAAGTGTCTAGAGCATCTGTTTTTCTTCAAGCTCATTGGTGACACC
CCCATCGACACCTTCCTCATGGAGATGCTTGAGGCTCCCCATCAACTGGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>9-cis retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II distal enhancer sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal placenta development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle cell differentiation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000663</id>
      <name>Retinoic acid receptor alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4312</ref-id>
            <pubmed-id>9204085</pubmed-id>
            <citation>Shroot B, Michel S: Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103.</citation>
          </article>
          <article>
            <ref-id>A4313</ref-id>
            <pubmed-id>9990415</pubmed-id>
            <citation>Griffiths CE, Ancian P, Humphries J, Poncet M, Rizova E, Michel S, Clucas A: Adapalene 0.1% gel and adapalene 0.1% cream stimulate retinoic acid receptor mediated gene transcription without significant irritative effects in the skin of healthy human volunteers. Br J Dermatol. 1998 Oct;139 Suppl 52:12-6.</citation>
          </article>
          <article>
            <ref-id>A4314</ref-id>
            <pubmed-id>9990413</pubmed-id>
            <citation>Michel S, Jomard A, Demarchez M: Pharmacology of adapalene. Br J Dermatol. 1998 Oct;139 Suppl 52:3-7.</citation>
          </article>
          <article>
            <ref-id>A4315</ref-id>
            <pubmed-id>9557255</pubmed-id>
            <citation>Shroot B, Michel S, Allec J, Chatelus A, Wagner N: A new concept of drug delivery for acne. Dermatology. 1998;196(1):165-70.</citation>
          </article>
          <article>
            <ref-id>A4316</ref-id>
            <pubmed-id>10651997</pubmed-id>
            <citation>Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10276" source="Swiss-Prot">
        <name>Retinoic acid receptor alpha</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5. Mediates retinoic acid-induced granulopoiesis.</specific-function>
        <gene-name>RARA</gene-name>
        <locus>17q21</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.95</theoretical-pi>
        <molecular-weight>50770.805</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9864</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RARA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X06614</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>36157</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RARA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR1B1</synonym>
          <synonym>Nuclear receptor subfamily 1 group B member 1</synonym>
          <synonym>RAR-alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001322|Retinoic acid receptor alpha
MASNSSSCPTPGGGHLNGYPVPPYAFFFPPMLGGLSPPGALTTLQHQLPVSGYSTPSPAT
IETQSSSSEEIVPSPPSPPPLPRIYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNM
VYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKEVPKPECSESYTL
TPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTV
EFAKQLPGFTTLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNA
GFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALK
VYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGL
DTLSGQPGGGGRDGGGLAPPPGSCSPSLSPSSNRSSPATHSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016168|Retinoic acid receptor alpha (RARA)
ATGGCCAGCAACAGCAGCTCCTGCCCGACACCTGGGGGCGGGCACCTCAATGGGTACCCG
GTGCCTCCCTACGCCTTCTTCTTCCCCCCTATGCTGGGTGGACTCTCCCCGCCAGGCGCT
CTGACCACTCTCCAGCACCAGCTTCCAGTTAGTGGATATAGCACACCATCCCCAGCCACC
ATTGAGACCCAGAGCAGCAGTTCTGAAGAGATAGTGCCCAGCCCTCCCTCGCCACCCCCT
CTACCCCGCATCTACAAGCCTTGCTTTGTCTGTCAGGACAAGTCCTCAGGCTACCACTAT
GGGGTCAGCGCCTGTGAGGGCTGCAAGGGCTTCTTCCGCCGCAGCATCCAGAAGAACATG
GTGTACACGTGTCACCGGGACAAGAACTGCATCATCAACAAGGTGACCCGGAACCGCTGC
CAGTACTGCCGACTGCAGAAGTGCTTTGAAGTGGGCATGTCCAAGGAGTCTGTGAGAAAC
GACCGAAACAAGAAGAAGAAGGAGGTGCCCAAGCCCGAGTGCTCTGAGAGCTACACGCTG
ACGCCGGAGGTGGGGGAGCTCATTGAGAAGGTGCGCAAAGCGCACCAGGAAACCTTCCCT
GCCCTCTGCCAGCTGGGCAAATACACTACGAACAACAGCTCAGAACAACGTGTCTCTCTG
GACATTGACCTCTGGGACAAGTTCAGTGAACTCTCCACCAAGTGCATCATTAAGACTGTG
GAGTTCGCCAAGCAGCTGCCCGGCTTCACCACCCTCACCATCGCCGACCAGATCACCCTC
CTCAAGGCTGCCTGCCTGGACATCCTGATCCTGCGGATCTGCACGCGGTACACGCCCGAG
CAGGACACCATGACCTTCTCGGACGGGCTGACCCTGAACCGGACCCAGATGCACAACGCT
GGCTTCGGCCCCCTCACCGACCTGGTCTTTGCCTTCGCCAACCAGCTGCTGCCCCTGGAG
ATGGATGATGCGGAGACGGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGACCGCCAG
GACCTGGAGCAGCCGGACCGGGTGGACATGCTGCAGGAGCCGCTGCTGGAGGCGCTAAAG
GTCTACGTGCGGAAGCGGAGGCCCAGCCGCCCCCACATGTTCCCCAAGATGCTAATGAAG
ATTACTGACCTGCGAAGCATCAGCGCCAAGGGGGCTGAGCGGGTGATCACGCTGAAGATG
GAGATCCCGGGCTCCATGCCGCCTCTCATCCAGGAAATGTTGGAGAACTCAGAGGGCCTG
GACACTCTGAGCGGACAGCCGGGGGGTGGGGGGCGGGACGGGGGTGGCCTGGCCCCCCCG
CCAGGCAGCTGTAGCCCCAGCCTCAGCCCCAGCTCCAACAGAAGCAGCCCGGCCACCCAC
TCCCCGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>actin cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-actinin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase A binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase B binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid-responsive element binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription corepressor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic cell clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to estrogen stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chondroblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>face development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>germ cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glandular epithelial cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>growth plate cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>limb development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of granulocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of translational initiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neural tube closure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>outflow tract septum morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-13 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-4 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-5 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 2 cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Sertoli cell fate commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spermatogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>trachea cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ureteric bud development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle cell differentiation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0000412</id>
      <name>Retinoic acid receptor RXR-alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10298</ref-id>
            <pubmed-id>8142113</pubmed-id>
            <citation>Bernard BA: Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993;6 Suppl 1:61-9.</citation>
          </article>
          <article>
            <ref-id>A4316</ref-id>
            <pubmed-id>10651997</pubmed-id>
            <citation>Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P19793" source="Swiss-Prot">
        <name>Retinoic acid receptor RXR-alpha</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.</specific-function>
        <gene-name>RXRA</gene-name>
        <locus>9q34.3</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.86</theoretical-pi>
        <molecular-weight>50810.835</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10477</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RXRA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X52773</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35885</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19793</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RXRA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR2B1</synonym>
          <synonym>Nuclear receptor subfamily 2 group B member 1</synonym>
          <synonym>Retinoid X receptor alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000821|Retinoic acid receptor RXR-alpha
MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPING
MGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVP
AHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLID
KRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAEL
AVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVIL
LRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDM
QMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLL
RLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0000820|1389 bp
ATGGACACCAAACATTTCCTGCCGCTCGATTTCTCCACCCAGGTGAACTCCTCCCTCACC
TCCCCGACGGGGCGAGGCTCCATGGCTGCCCCCTCGCTGCACCCGTCCCTGGGGCCTGGC
ATCGGCTCCCCGGGACAGCTGCATTCTCCCATCAGCACCCTGAGCTCCCCCATCAACGGC
ATGGGCCCGCCTTTCTCGGTCATCAGCTCCCCCATGGGCCCCCACTCCATGTCGGTGCCC
ACCACACCCACCCTGGGCTTCAGCACTGGCAGCCCCCAGCTCAGCTCACCTATGAACCCC
GTCAGCAGCAGCGAGGACATCAAGCCCCCCCTGGGCCTCAATGGCGTCCTCAAGGTCCCC
GCCCACCCCTCAGGAAACATGGCTTCCTTCACCAAGCACATCTGCGCCATCTGCGGGGAC
CGCTCCTCAGGCAAGCACTATGGAGTGTACAGCTGCGAGGGGTGCAAGGGCTTCTTCAAG
CGGACGGTGCGCAAGGACCTGACCTACACCTGCCGCGACAACAAGGACTGCCTGATTGAC
AAGCGGCAGCGGAACCGGTGCCAGTACTGCCGCTACCAGAAGTGCCTGGCCATGGGCATG
AAGCGGGAAGCCGTGCAGGAGGAGCGGCAGCGTGGCAAGGACCGGAACGAGAATGAGGTG
GAGTCGACCAGCAGCGCCAACGAGGACATGCCGGTGGAGAGGATCCTGGAGGCTGAGCTG
GCCGTGGAGCCCAAGACCGAGACCTACGTGGAGGCAAACATGGGGCTGAACCCCAGCTCG
CCGAACGACCCTGTCACCAACATTTGCCAAGCAGCCGACAAACAGCTTTTCACCCTGGTG
GAGTGGGCCAAGCGGATCCCACACTTCTCAGAGCTGCCCCTGGACGACCAGGTCATCCTG
CTGCGGGCAGGCTGGAATGAGCTGCTCATCGCCTCCTTCTCCCACCGCTCCATCGCCGTG
AAGGACGGGATCCTCCTGGCCACCGGGCTGCACGTCCACCGGAACAGCGCCCACAGCGCA
GGGGTGGGCGCCATCTTTGACAGGGTGCTGACGGAGCTTGTGTCCAAGATGCGGGACATG
CAGATGGACAAGACGGAGCTGGGCTGCCTGCGCGCCATCGTCCTCTTTAACCCTGACTCC
AAGGGGCTCTCGAACCCGGCCGAGGTGGAGGCGCTGAGGGAGAAGGTCTATGCGTCCTTG
GAGGCCTACTGCAAGCACAAGTACCCAGAGCAGCCGGGAAGGTTCGCTAAGCTCTTGCTC
CGCCTGCCGGCTCTGCGCTCCATCGGGCTCAAATGCCTGGAACATCTCTTCTTCTTCAAG
CTCATCGGGGACACACCCATTGACACCTTCCTTATGGAGATGCTGGAGGCGCCGCACCAA
ATGACTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF11825</identifier>
            <name>Nuc_recep-AF1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>RNA polymerase II transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>9-cis retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid-responsive element binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II regulatory region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal placenta development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>midgut development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modulation by virus of host morphology or physiology</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peroxisome proliferator activated receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of translational initiation by iron</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of branching involved in prostate gland morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of myelination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to selenium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular cardiac muscle tissue morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000262</id>
      <name>Prostaglandin G/H synthase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33330</ref-id>
            <pubmed-id>18821215</pubmed-id>
            <citation>Hung LF, Lai JH, Lin LC, Wang SJ, Hou TY, Chang DM, Liang CC, Ho LJ: Retinoid acid inhibits IL-1-induced iNOS, COX-2 and chemokine production in human chondrocytes. Immunol Invest. 2008;37(7):675-93. doi: 10.1080/08820130802307237.</citation>
          </article>
          <article>
            <ref-id>A33331</ref-id>
            <pubmed-id>17673467</pubmed-id>
            <citation>Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM, Jones DA: Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli. J Biol Chem. 2007 Oct 5;282(40):29394-400. doi: 10.1074/jbc.M609768200. Epub 2007 Aug 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35354" source="Swiss-Prot">
        <name>Prostaglandin G/H synthase 2</name>
        <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
        <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.</specific-function>
        <gene-name>PTGS2</gene-name>
        <locus>1q25.2-q25.3</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>7.41</theoretical-pi>
        <molecular-weight>68995.625</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGS2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L15326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291988</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1376</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35354</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PGH2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.99.1</synonym>
          <synonym>COX-2</synonym>
          <synonym>COX2</synonym>
          <synonym>Cyclooxygenase-2</synonym>
          <synonym>PGH synthase 2</synonym>
          <synonym>PGHS-2</synonym>
          <synonym>PHS II</synonym>
          <synonym>Prostaglandin H2 synthase 2</synonym>
          <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021832|Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03098</identifier>
            <name>An_peroxidase</name>
          </pfam>
          <pfam>
            <identifier>PF00008</identifier>
            <name>EGF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonate 15-lipoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peroxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin-endoperoxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to fluid shear stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to UV</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclooxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hair cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of blood-brain barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>movement of cell or subcellular component</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>NAD metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nicotinamide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fever generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibroblast growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of platelet-derived growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transforming growth factor beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fructose</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lithium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to manganese ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to tumor necrosis factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>